Brief: Ondine Biomedical Says LANTERN Phase 3 Study To Report Top-Line Results In Spring 2026
10/03/2026 07:50
March 10 (Reuters) - Ondine Biomedical Inc OBI.L: ONDINE BIOMEDICAL - ONDINE PROVIDES UPDATE ON US PHASE 3 PIVOTAL STUDY ONDINE BIOMEDICAL INC - LANTERN PHASE 3 STUDY TO REPORT TOP-LINE RESULTS IN SPRING 2026 Source text: ID:nRSJ0241Wa Further company coverage: OBI.L ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Ondine Biomedical
See all newsAIM Ondine Biomedical - Capital Access Window - Ondine Biomedical Inc
Brief: Ondine Biomedical Confirms Total Gross Proceeds From Placing And Subscription Are £10 Million
Ondine Biomedical - Result of Fundraise, Restoration of Trading & TVR
Brief: Ondine Biomedical Announces A Proposed Fundraising Of About £10 Mln
Ondine Biomedical - Proposed c.£10m (C$18.88m) Fundraise